title: A hypofractionated radiotherapy schedule with 57.75Gy in 21 fractions for T1-2N0 prostate carcinoma: Analysis of late toxicity and efficacy.
abstract: OBJECTIVE
  The primary endpoint was to assess the late toxicity of a hypofractionated radiotherapy schedule in relation to radiation parameters concerning the rectum and bladder. The second endpoint was to assess a composite of biochemical and clinical failure.
  
  
  METHODS
  Sixty-four prospectively selected patients diagnosed with localized low risk prostate cancer, Gleason score (GS) <7, PSA <10, and T1-2N0, were treated with external 3- dimensional conformal radiotherapy (3D-CRT). Patients received 57.75 Gy in 21 daily fractions of 2.75 Gy/fraction.
  
  
  RESULTS
  Late gastrointestinal (GI) toxicity was as follows: grade 0: 47 (73.4 %) patients, grade 1: 12 (19.2 %), grade 2: 4 (6.3%), and grade 3: 1 (1.6%). There was a significant correlation between D50, V70 and EORTC/RTOG late rectal toxicity score (p<0.001 and p=0.006, respectively). Grade 1 and 2 late bladder toxicity was seen in 4.7 and 1.6% of the patients, respectively. With a median follow up of 18 months no biochemical relapse was observed.
  
  
  CONCLUSIONS
  The present study supports the use of hypofractionated radiation therapy which showed a high therapeutic ratio with acceptable toxicity and no biochemical relapse during follow-up.
authors.affiliation: Kapodistrian University of Athens, Medical School, 2nd Radiology Department, Radiotherapy Unit, Attikon Hospital, Athens, Greece.
authors.forename: Vassilis
authors.initials: V
authors.lastname: Kouloulias
authors.forename: Anna
authors.initials: A
authors.lastname: Zygogianni
authors.forename: Ioanna
authors.initials: I
authors.lastname: Kantzou
authors.forename: Maria
authors.initials: M
authors.lastname: Tolia
authors.forename: Kalliopi
authors.initials: K
authors.lastname: Platoni
authors.forename: C
authors.initials: C
authors.lastname: Antypas
authors.forename: Demetrios
authors.initials: D
authors.lastname: Chaldeopoulos
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Pantelakos
authors.forename: Argyrios
authors.initials: A
authors.lastname: Siatelis
authors.forename: Michael
authors.initials: M
authors.lastname: Chrysofos
authors.forename: Ivelina
authors.initials: I
authors.lastname: Beli
authors.forename: Maria
authors.initials: M
authors.lastname: Dilvoi
authors.forename: Ioannis
authors.initials: I
authors.lastname: Georgakopoulos
authors.forename: George
authors.initials: G
authors.lastname: Sarris
authors.forename: John
authors.initials: J
authors.lastname: Kouvaris
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Kelekis
mesh_terms: D000368:Aged; D019583:Dose Fractionation, Radiation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects; D012007:Rectum / Q000528:radiation effects; D001743:Urinary Bladder / Q000528:radiation effects